Literature DB >> 3472019

PER-117: a new human ALL cell line with an immature thymic phenotype.

U R Kees, J Ford, P J Price, B F Meyer, R P Herrmann.   

Abstract

A new cell line, PER-117, was established from bone marrow cells of an eighteen months old boy with an acute lymphoblastic leukaemia (ALL). The leukaemic origin of cell line PER-117 is indicated by its cytochemical, immunological and cytogenetic similarity to the patient's fresh leukaemic cells. PER-117 carries a marker chromosome which was identified as a translocation between chromosomes 1 and 11. The surface marker analysis revealed that the phenotype of PER-117 is RFB-1+, RFT-1+ (CD5), 3A1+ (CD7), OKT 9+, OKT 10+ and HLA-DR-. Thus, this cell line appears to represent a prothymocyte or stage I thymocyte and preliminary data suggest that it can be induced in vitro to further differentiate.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3472019     DOI: 10.1016/0145-2126(87)90082-8

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  10 in total

1.  Synergistic action of stem-cell factor and interleukin-7 in a human immature T-cell line.

Authors:  U R Kees; J Ford
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

2.  Requirements for the induction of the interleukin-2 receptor complex in a human pre-T-cell line.

Authors:  P D Salvati; S E Peroni; P R Ranford; U R Kees
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

3.  High expression of connective tissue growth factor accelerates dissemination of leukaemia.

Authors:  J E Wells; M Howlett; H M Halse; J Heng; J Ford; L C Cheung; A L Samuels; M Crook; A K Charles; C H Cole; U R Kees
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

4.  Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines.

Authors:  A H Beesley; M-L Palmer; J Ford; R E Weller; A J Cummings; J R Freitas; M J Firth; K U Perera; N H de Klerk; U R Kees
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640

5.  Deregulation of polycomb repressor complex 1 modifier AUTS2 in T-cell leukemia.

Authors:  Stefan Nagel; Claudia Pommerenke; Corinna Meyer; Maren Kaufmann; Hans G Drexler; Roderick A F MacLeod
Journal:  Oncotarget       Date:  2016-07-19

6.  Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia.

Authors:  Laurence C Cheung; Rebecca de Kraa; Joyce Oommen; Grace-Alyssa Chua; Sajla Singh; Anastasia M Hughes; Emanuela Ferrari; Jette Ford; Sung K Chiu; Ronald W Stam; Ursula R Kees; Sébastien Malinge; Rishi S Kotecha
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

7.  NK-like homeodomain proteins activate NOTCH3-signaling in leukemic T-cells.

Authors:  Stefan Nagel; Letizia Venturini; Grzegorz K Przybylski; Piotr Grabarczyk; Corinna Meyer; Maren Kaufmann; Karin Battmer; Christian A Schmidt; Hans G Drexler; Michaela Scherr; Roderick Af Macleod
Journal:  BMC Cancer       Date:  2009-10-19       Impact factor: 4.430

8.  Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism.

Authors:  A H Beesley; M J Firth; J Ford; R E Weller; J R Freitas; K U Perera; U R Kees
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

9.  Transcriptional activation of prostate specific homeobox gene NKX3-1 in subsets of T-cell lymphoblastic leukemia (T-ALL).

Authors:  Stefan Nagel; Stefan Ehrentraut; Jürgen Tomasch; Stefan Lienenklaus; Björn Schneider; Robert Geffers; Corinna Meyer; Maren Kaufmann; Hans G Drexler; Roderick A F MacLeod
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

10.  Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL.

Authors:  L Fransecky; M Neumann; S Heesch; C Schlee; J Ortiz-Tanchez; S Heller; M Mossner; S Schwartz; L H Mochmann; K Isaakidis; L Bastian; U R Kees; T Herold; K Spiekermann; N Gökbuget; C D Baldus
Journal:  J Hematol Oncol       Date:  2016-09-22       Impact factor: 17.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.